Jump to content
  • Black Friday 2020

    25% off courses, webcasts, eLearning, booklets.

    More Information
  • Renew Now

    It's time to renew your membership for 2021.

    Click Here
  • RQA Careers Area

    Providing valuable opportunities to enhance your profession

    View Now

*Please note that while still operational, the RQA office is being run remotely, so please bear with us if we take a little longer than usual to deal with any queries*

Who are RQA

The Research Quality Association (RQA) is a professional membership body dedicated to informing and advancing its members. We provide status and visibility for individuals engaged in the quality of research concerning pharmaceuticals, agrochemicals, chemicals and medical devices. Since our inception in 1977, the Association has increased and evolved to reflect regulatory changes, the growing impact of regulatory inspection and the ever-changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research.  

Read more+

Our vision

To inspire quality, integrity and compliance in scientific research.

Our mission

To provide knowledge and learning in the scientific research community by building expertise through training, communication, engagement and collaboration.


Sign up to the latest news and events.

Latest News

View all news

EMA - COVID-19 Vaccines

The European Medicines Agency has published information on the development and evaluation of vaccines for COVID-19.

Read more+

EMA - Consideration on core requirements for RMPs of COVID19 vaccines

Consideration on core requirements for RMPs of COVID19 vaccines coreRMP19 guidance Introduction/Background In addition to the EMA guidance on pharmacovigilance and vaccine development, the EMA will issue the “Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines” giving an overview of the monitoring activities to be carried out in the EU for COVID-19 vaccines, including the roles, responsibilities and interactions of the stakeholders involved. Further interactions between EMA, NCAs, and the vaccine manufacturers have identified the need to develop further guidance on RMP requirements for COVID-19 vaccines.

Read more+

EMA - November 2020 PRAC Highlights

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 November 2020

Read more+
Southampton Clinical Trials Unit
Thames Valley,
Bio Pharma Resourcing